Optometric ManagementRethinking the Dry Eye Disease Stepladder

🎓 Expert Commentary / Peer Perspective

TFOS DEWS III reframes dry eye disease as a multifactorial, symptomatic condition that should be diagnosed consistently, subtyped by underlying etiological drivers, and managed through layered, mechanism-based therapy. The report shifts clinicians away from rigid treatment escalation models and toward individualized care targeting tear film deficiencies, eyelid abnormalities, and ocular surface disease.

Clinical Considerations

• DEWS III recommends combining validated symptom assessment with objective evidence of tear film homeostasis loss before diagnosis.
• The updated framework emphasizes identifying dominant disease drivers rather than relying solely on aqueous-deficient versus evaporative classifications.
• Meibomian gland dysfunction and lid disease often require earlier targeted intervention, including procedural therapies when clinically appropriate.
• Management commonly requires combination therapy addressing multiple concurrent contributors to symptoms and ocular surface instability.

Practice Applications

• Recognize dry eye as a chronic, multifactorial disease requiring structured assessment.
• Match treatment intensity to identified etiological drivers.
• Monitor symptoms and objective findings longitudinally using standardized tools.
• Educate patients and staff using consistent disease-framework messaging.